Shire plc, of Dublin, completed the sale of its oncology franchise to Servier S.A.S. for $2.4 billion. David Lee, who was previously the head of Shire's Global Genetic Diseases and Oncology franchises, will continue with Servier as CEO of its new U.S. commercial subsidiary, Servier Pharmaceuticals.